SynthesisMedicina oral, patologia oral y cirugia bucal2020
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis.
Synthesis in Medicina oral, patologia oral y cirugia bucal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05378334 (Efficacy and Safety of Bone-protecting and Mass-dispersesing Decoction), which is not on this map. Cited by 77 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Bone-protecting and Mass-dispersesing Decoction (HuGuXiaoJiTang, HGXJT) Combining With ICIs in Bone Metastatic NSCLC Patients
Who cites it
77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Impact of photobiomodulation in the management of medication-related osteonecrosis of the jaw : a systematic review.Lasers in medical science · 2025Pooled it
- Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Incidence and associated factors of medication-related osteonecrosis of the jaw in breast cancer patients with bone metastases: a nationwide registry study in Finland.Clinical oral investigations · 2026Article
- MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors.Bone reports · 2026Article
- Clinical Characteristics and Serum Vitamin D Levels in Patients with MRONJ Associated with Antiresorptive Therapy: A Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- Medication-related osteonecrosis of the jaw in multiple myeloma patients: a case series.British dental journal · 2026Article
- Development of a Machine Learning-Based Triage Score for Medication-Related Osteonecrosis of the Jaw in Osteoporosis Patients Undergoing Tooth Extraction.Diagnostics (Basel, Switzerland) · 2026Article
- [Expert consensus on perioperative management of tooth extraction in patients receiving denosumab therapy].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026Article
- Uncovering jaw-specific radiographic differences in medication related osteonecrosis of the jaws (MRONJ): a case-control study.Clinical oral investigations · 2026Article
- Evaluation of Osteonecrosis Risk Using Serum C-Terminal Cross-Linked Telopeptide of Type 1 Collagen (CTX-1) Levels in Osteoporotic Patients: Effects of Drug Holidays and Risk Factors.The Eurasian journal of medicine · 2026Article
- Radiographic Patterns and Clinical Correlates of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Retrospective Analysis.Journal of clinical medicine · 2026Article
- Double-edged-sword effect of bisphosphonates on the osteogenic differentiation of human periodontal ligament stem cells.Frontiers in pharmacology · 2026Article
- Endodontic treatment and management of patients under antiresorptive treatment: a scoping review on MRONJ risk.Clinical oral investigations · 2025Article
- Peri-implant inflammation increases the risk of osteonecrosis in mice treated with bisphosphonate.Journal of periodontology · 2025Article
- Article
- Introducing equivalent and threshold doses in the assessment of medication-related osteonecrosis of the jaw risk: insights from a descriptive study in Iran.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Article
- Comparison of the effects of zoledronic acid versus denosumab on bone metabolism, inflammatory response, and immunoglobulins in breast cancer patients with bone metastases.Journal of medical biochemistry · 2025Article
- Clinical Effectiveness of Surgical Marginal Resection with Piezoelectric Device on Bisphosphonate-Related Osteonecrosis of the Jaws: A Retrospective Study.Journal of clinical medicine · 2025Article
- Incidence of medication-related osteonecrosis of the jaw and associated antiresorptive drugs in adult Finnish population.Scientific reports · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the present study was to analyse the incidence, risk ratio (RR) and prognoses of two types of medication-related osteonecrosis of the jaws (MRONJ): denosumab-related osteonecrosis of the jaws (DRONJ) and Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ) in cancer patients under treatment with denosumab or zoledronic acid (ZA). MATERIAL AND
methodsAn electronic and manual search was conducted for randomized controlled trials (RCTs) until May 2019. Assessment of the identified studies, risk of bias and data extraction were performed independently by two reviewers. The incidence of DRONJ and BRONJ and the RR to develop MRONJ were calculated at 1 year, 2 years and 3 years of exposure. It was also calculated the odds ratio (OR) of their respective prognoses. They were calculated normalizing the values of the individual studies to 1 year, 2 years or 3 years when necessary through robust regression models using a statistical program.
resultsFrom 1.277 references identified, 8 RCTs were included, which comprised a total of 13.857 patients with a variety of neoplasms. The incidence of DRONJ in cancer patients under treatment with denosumab ranged from 0.5 to 2.1% after 1 year, 1.1 to 3.0% after 2 years, and 1.3 to 3.2% after 3 years of exposure. The incidence of BRONJ in cancer patients under treatment with ZA ranged from 0.4 to 1.6% after 1 year of exposure, 0.8 to 2.1% after 2 years, and 1.0 to 2.3% after 3 years of exposure. Statistically significant differences were found between denosumab and ZA in the risk of developing MRONJ after 1, 2 and 3 years of exposure. Nevertheless, there were no significant differences in terms of patient prognosis.
conclusionsDenosumab is associated with a significantly higher risk of developing MRONJ compared to ZA. Nevertheless, no differences were found in its prognoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.